How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,348 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)

AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 157, Issue 3, Pages 851–854 AGA Clinical Practice (...) Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) x Walter Smalley Affiliations Department of Medicine, Division of Gastroenterology, Vanderbilt University School of Medicine, Nashville, Tennessee Veterans Affairs Tennessee Valley Health Care System, Nashville, Tennessee 1 , 2 , x Corinna Falck-Ytter Affiliations Departments of Medicine and Gastroenterology, Case Western Reserve University, Cleveland, Ohio Veterans Affairs

2019 American Gastroenterological Association Institute

2. Diarrhea Secondary to Medications

Diarrhea Secondary to Medications Diarrhea Secondary to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea Secondary (...) to Medications Diarrhea Secondary to Medications Aka: Diarrhea Secondary to Medications , Drug-Induced Diarrhea , Medication-Induced Diarrhea From Related Chapters II. Causes: Medication Class See s (e.g. ) s Amoxicillan-Clavulanate ( ) Chemotherapeutic agents Antiinflammatory medications S s ( ) Antihypertensives s s ( ) May cause a sprue-like not seen with other s Endocrine agents ( ) ( ) ( ) Gastrointestinal Agents or calcium containing s s (e.g. , senna) s (e.g. ) s (e.g. ) Metoclopramide (Reglan

2018 FP Notebook

3. Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs

throughout the trial, and average drinks per day. To evaluate changes in serum electrolytes before and after administration of Eenterade®. To assess intravenous fluid requirement and/or hospitalization for dehydration secondary to diarrhea between control observation period and active Enterade® period. To evaluate difference in utilization of standard-of-care anti-diarrheal medications between control observation period and Enterade® period. To compare subjective feeling of bloating and flatulence before (...) Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2018 Clinical Trials

4. Medications for the prevention and treatment of travellers' diarrhea. (PubMed)

Medications for the prevention and treatment of travellers' diarrhea. . Travellers' diarrhea (TD) remains one of the most common illnesses encountered by travellers to less developed areas of the world. Because bacterial pathogens such as enterotoxigenic Escherichia coli (ETEC), enteroaggregative E. coli , Campylobacter spp. and Shigella spp. are the most frequent causes, antibiotics have been useful in both prevention and treatment of TD.Results of trials that assessed the use of medications (...) for the prevention and treatment of TD were identified through PubMed and MEDLINE searches using search terms 'travellers' diarrhea', 'prevention' and 'treatment'. References of articles were also screened for additional relevant studies.Prevention of TD with antibiotics has been recommended only under special circumstances. Doxycycline, trimethoprim-sulfamethoxazole, fluoroquinolones and rifaximin have been used for prevention, but at present the first three antibiotics may have limited use secondary

Full Text available with Trip Pro

2017 Journal of Travel Medicine

5. Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

of Travelers’ Diarrhea DuPont et al [113] Medical Considerations Before International Travel Freedman et al [207] The Yellow Book CDC Travelers Health CDC Immunocompromised hosts Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents CDC/NIH/HIVMA/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children CDC/NIH/HIVMA/IDSA Foodborne and waterborne Surveillance for Foodborne Disease Outbreaks (...) at Home and to Animals in Public Settings: Risks to Children Pickering et al [51] Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative Rubin et al [208] Mode Title URL Author/Issuing Agency International travel Expert Review of the Evidence Base for Prevention of Travelers’ Diarrhea DuPont et al [113] Medical Considerations Before International Travel Freedman et al [207] The Yellow Book CDC Travelers Health CDC Immunocompromised hosts Guidelines

2017 Infectious Diseases Society of America

6. Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.

in the prevention of antibiotic induced diarrhea and Clostridium difficile diarrhea. The chosen population consists of 190 hospitalized patients taking antibiotics. Preselected and randomized patients will take probiotics once daily until 1 week after the course of antibiotic is over or a placebo with 0 CFU. The primary outcome is to detect the occurrence of an antibiotic-associated diarrhea. The secondary outcome is to assess the presence of Clostridium difficile toxins in stool culture. Condition or disease (...) stools for a period greater than 3 days and which is considered by the patient as an increase in stool quantity compared to regular basis, evaluated in a patient on antibiotics. Secondary Outcome Measures : Presence of Clostridium difficile toxins in stool culture. [ Time Frame: Upon eventual onset of diarrhea, from the first day of inclusion in the trial and up to a month after the antibiotic regimen is stopped; in hospitalized patients only. ] Presence of Clostridium difficile toxins

2018 Clinical Trials

7. Cardiovascular Disease: Secondary Prevention

Organization diagnostic criteria—who have failed to achieve an LDL 400 mg/dL. Bile acid sequestrants should be avoided for patients with TG = 300 mg/dL. • Cholestyramine has many drug interactions due to its ability to reduce absorption of other medications. Other drugs should be administered at least 1 hour before or 4–6 hours after cholestyramine. 9 ACE Inhibitor or ARB Therapy Table 3. ACE inhibitor or ARB therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st ACE (...) ) or PCI with stent. Table 4. Antiplatelet therapy for secondary prevention of ASCVD Line Medication Initial dose Maximum dose 1 st Aspirin 81 mg daily 81 mg daily 2 nd Clopidogrel 1 75 mg daily 75 mg daily 1 Clopidogrel is equally effective in patients with ASCVD who have a contraindication or intolerance to aspirin. 10 Lowering Triglycerides to Prevent Pancreatitis Triglycerides do not require investigation or treatment unless they are higher than 500 mg/dL. (Treatment/investigation at higher than

2018 Kaiser Permanente Clinical Guidelines

8. Are Probiotics Effective In Preventing Clostridium Difficile Associated Diarrhea?

controlled trials of participants aged 5 to 74 years who were on antibiotics and received a probiotic, placebo, or no treatment control. Participants were followed for a range of 7 days to 3 months. Johnston et al. found that diarrhea secondary to C. difficile occurred in 2% of patients receiving probiotics compared to 5.9% of controls, with a relative risk reduction (RRR) of 66% (95% confidence interval 51 to 76) [4] and number needed to treat (NNT) of 26 patients to prevent one case of CDAD (...) Langone Medical Center Peer reviewed by Melanie Maslow, MD, section editor, pharmacology, Clinical Correlations Image courtesy of Wikimedia Commons References: 1. McFarland, L.V., Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol, 2008. 3(5): p. 563-78. 2. Ghantoji, S.S., et al., Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect, 2010. 74(4): p. 309-18. 3. Friedman, G., The role of probiotics in the prevention

Full Text available with Trip Pro

2014 Clinical Correlations

9. Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. (PubMed)

), PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Biological Medical Database (CBM, SinoMed), China Science and Technology Journal Database (VIP), and Wan Fang Data. Meanwhile, pooled estimates, including the 95% confidence interval (CI), were calculated for primary and secondary outcomes of IBS-D patients. Besides, quality of relevant articles was evaluated using the Cochrane Collaboration's risk of bias tool, and the Review Manager 5.3 and Stata12.0 softwares were employed (...) Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. To comprehensively evaluate the efficacy and safety of acupuncture combined with Chinese herbal medicine (CHM) in treating irritable bowel syndrome with diarrhea (IBS-D).Relevant randomized controlled trials (RCTs) were systemically retrieved from electronic databases from inception to March 2018, including the Cochrane Central Register of Controlled Trials (CENTRAL

Full Text available with Trip Pro

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

10. Management of Cancer Medication-Related Infusion Reactions

acetylsalicylic acid as routine pre-medications in the secondary prophylaxis setting; however, based on expert consensus, it can be a reasonable approach. 102 Key re-challenge recommendations by medication 3.2 Anticancer Medication Class: Class of Medication Recommendations Taxanes (Recommendation 6.2, Recommendation 6.3) • If a patient experiences an IR with a taxane (e.g. paclitaxel), there is insufficient evidence to recommend re-challenge with a different taxane (e.g. docetaxel) due to high rates of cross (...) Management of Cancer Medication-Related Infusion Reactions Management of Cancer Medication- Related Infusion Reactions Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind

2019 Cancer Care Ontario

11. Diarrhea Secondary to Medications

Diarrhea Secondary to Medications Diarrhea Secondary to Medications Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Diarrhea Secondary (...) to Medications Diarrhea Secondary to Medications Aka: Diarrhea Secondary to Medications , Drug-Induced Diarrhea , Medication-Induced Diarrhea From Related Chapters II. Causes: Medication Class See s (e.g. ) s Amoxicillan-Clavulanate ( ) Chemotherapeutic agents Antiinflammatory medications S s ( ) Antihypertensives s s ( ) May cause a sprue-like not seen with other s Endocrine agents ( ) ( ) ( ) Gastrointestinal Agents or calcium containing s s (e.g. , senna) s (e.g. ) s (e.g. ) Metoclopramide (Reglan

2015 FP Notebook

12. A Study of Colesevelam for Lenalidomide-Associated Diarrhea

lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease (...) . The primary end-point is improvement of diarrhea to grade 1 or better according to the CTCAE 5.0 scale by 4 weeks of treatment with colesevelam. Secondary Outcome Measures : GI symptom assessment [ Time Frame: 4 weeks ] To assess GI symptoms using Patient Reported Outcomes within the Common Terminology Criteria for Adverse Events Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2018 Clinical Trials

13. Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

14. Efficacy Of Probiotics vs. Zinc vs. Probiotics-Zinc Combination On Acute Diarrhea In Children

of zinc to the standard treatment. The third group will be managed by the addition to a combination of zinc and probiotics to standard treatment. The patients will be followed to compare the effect of the given medication on the duration of diarrhea. Condition or disease Intervention/treatment Phase Acute Diarrhea Other: Probiotics Other: Zinc Other: Probiotics & Zinc Other: Standard care Not Applicable Detailed Description: This is a prospective, randomized, double blinded, clinical trial (...) will receive a combination of probiotics (saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day. Upon assigning the group (A, B or C), the patient will receive his daily dose of medication in a sealed opaque tiny bag prepared by the nursing staff by adding 5 ml water to the assigned medication which will be unknown to both parent and researcher. Patients will be assessed on a daily basis. The quality and quantity of diarrhea, as well

2018 Clinical Trials

15. Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics (R61)

effects of antibiotic medications. One of the most common indications for probiotics is for prevention of antibiotic-associated diarrhea. Clinically, different probiotic strains have demonstrated the ability to prevent AAD; however, the mechanism of action behind this effect has not been elucidated. Data from several studies suggest that antibiotic-induced disruption of commensal bacteria in the colon results in a significant (up to 50%) reduction in short chain fatty acid (SCFA) production (...) of the study product Has telephone access Exclusion Criteria: Any chronic condition, such as diabetes or asthma, that requires medication Allergy to strawberry Active diarrhea (three or more loose stools per day for two consecutive days) Any gastrointestinal medications, i.e. medicines for irritable bowel syndrome, gastroesophageal reflux disease, inflammatory bowel disease, etc. (a full medication list will be reviewed by the PIs prior to enrollment) History of heart disease, including valvulopathies

2018 Clinical Trials

16. Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes. Other Name: Pepto Bismol Placebo Comparator: Placebo Placebo oral tablet 4 bid Drug: Placebo Oral Tablet Placebo manufactured to mimic pepto bismol Outcome Measures Go to Primary Outcome Measures : Traveler's diarrhea [ Time Frame: Change from baseline through 10 days post-travel ] Self-reported TD Secondary Outcome Measures : Gut AMR genes [ Time Frame: Once within 7 days (before travel); once (...) Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bismuth

2018 Clinical Trials

17. Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea

/watery stool before recovery or end of study treatment (treatment duration maximal 5 days) [ Time Frame: 5 days ] Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary Secondary Outcome Measures : Number of recovered subjects per treatment group [ Time Frame: 5 days ] Number of recovered subjects per treatment group Global Physician Assessment at the end of treatment [ Time Frame: 5 days ] scores 1-6 Eligibility Criteria Go (...) : No Criteria Inclusion Criteria: Signed informed consent from one of the parent(s)/caregiver(s) or subject informed assent Children and adolescents, both genders, age from 3 months to < 18 years of age Confirmed diagnosis of acute diarrhea (defined as the passage of three or more unformed or liquid stools within the last 24 hours and lasting for less than three days) Females of child-bearing potential should agree to continue using a medically acceptable method of birth control throughout the study

2018 Clinical Trials

18. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome

Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03457324 Recruitment Status

2018 Clinical Trials

19. Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea

duration maximal 5 days [ Time Frame: 5 days ] Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary Secondary Outcome Measures : Number of recovered subjects [ Time Frame: 5 days ] Number of recovered subjects Global Physician Assessment at the end of treatment [ Time Frame: 5 days ] scores 1-6 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

20. Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence

Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence (ELXDFI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03489265 Recruitment Status

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>